CLIC-01: Manufacture and distribution of non-cryopreserved CAR-T cells for patients with CD19 positive hematologic malignancies

Access to commercial CD19 CAR-T cells remains limited even in wealthy countries like Canada due to clinical, logistical, and financial barriers related to centrally manufactured products. We created a non-commercial academic platform for end-to-end manufacturing of CAR-T cells within Canada’s public...

Descripción completa

Detalles Bibliográficos
Autores principales: Kekre, Natasha, Hay, Kevin A., Webb, John R., Mallick, Ranjeeta, Balasundaram, Miruna, Sigrist, Mhairi K., Clement, Anne-Marie, Nielsen, Julie S., Quizi, Jennifer, Yung, Eric, Brown, Scott D., Dreolini, Lisa, Waller, Daniel D., Smazynski, Julian, Gierc, Nicole S., Loveless, Bianca C., Clark, Kayla, Dyer, Tyler, Hogg, Richard, McCormick, Leah, Gignac, Michael, Bell, Shanti, Chapman, D. Maria, Bond, David, Yong, Siao, Fung, Rachel, Lockyer, Heather M., Hodgson, Victoria, Murphy, Catherine, Subramanian, Ana, Wiebe, Evelyn, Yoganathan, Piriya, Medynski, Liana, Vaillan, Dominique C., Black, Alice, McDiarmid, Sheryl, Kennah, Michael, Hamelin, Linda, Song, Kevin, Narayanan, Sujaatha, Rodrigo, Judith A., Dupont, Stefany, Hawrysh, Terry, Presseau, Justin, Thavorn, Kednapa, Lalu, Manoj M., Fergusson, Dean A., Bell, John C., Atkins, Harold, Nelson, Brad H., Holt, Robert A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9806210/
https://www.ncbi.nlm.nih.gov/pubmed/36601119
http://dx.doi.org/10.3389/fimmu.2022.1074740

Ejemplares similares

Ejemplares similares